Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18902255 | TRANSGENIC ANGELFISH | September 2024 | July 2025 | Allow | 9 | 2 | 1 | Yes | No |
| 18760465 | MOUSE HAVING A HUMANIZED B-CELL ACTIVATING FACTOR GENE | July 2024 | October 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18660825 | TRANSGENIC CORY | May 2024 | May 2025 | Abandon | 13 | 2 | 1 | Yes | No |
| 18622113 | ANTICANCER T CELL THERAPY PRODUCT-ASSISTING COMPOSITION COMPRISING DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY AND USE THEREOF | March 2024 | July 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18433553 | MEDIA FOR CULTURING NAIVE HUMAN PLURIPOTENT STEM CELLS | February 2024 | March 2026 | Allow | 25 | 2 | 1 | No | No |
| 18413219 | MOUSE HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GENE | January 2024 | April 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18539589 | METHOD FOR PRODUCING DOPAMINERGIC NEURON PROGENITOR CELL | December 2023 | August 2025 | Allow | 20 | 2 | 0 | Yes | No |
| 18526758 | METHODS FOR TARGETED INSERTION OF DNA IN GENES | December 2023 | December 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18526745 | METHODS FOR TARGETED INSERTION OF DNA IN GENES | December 2023 | April 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18446243 | GENE THERAPY FOR TREATING HEMOPHILIA A | August 2023 | October 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18363453 | CNS GENE DELIVERY USING PERIPHERAL ADMINISTRATION OF AAV VECTORS | August 2023 | March 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18347487 | CHIMERIC ANTIGEN RECEPTOR COMPRISING BCMA NANOBODY LINKED TO A CHIMERIC INTRACELLULAR SIGNALING DOMAIN | July 2023 | August 2024 | Allow | 13 | 1 | 2 | Yes | No |
| 18259828 | TRANSGENIC CORY | June 2023 | November 2025 | Allow | 28 | 2 | 0 | Yes | No |
| 18335959 | HUMAN LIVER CHIMERIC NON-HUMAN ANIMAL WITH DEFICIENT P450 OXIDOREDUCTASE AND METHODS OF USING SAME | June 2023 | August 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18325321 | IMPORTATION OF MITOCHONDRIAL PROTEIN BY AN ENHANCED ALLOTOPIC APPROACH | May 2023 | January 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18134824 | PLACENTA-DERIVED MATRIX AND METHODS OF PREPARING AND USE THEREOF | April 2023 | January 2026 | Abandon | 33 | 2 | 0 | No | No |
| 18134095 | ANTI-VEGF ANTIBODY CONSTRUCTS | April 2023 | June 2025 | Allow | 26 | 4 | 1 | Yes | No |
| 18166813 | Animal Models and Therapeutic Molecules | February 2023 | June 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18059809 | Animal Models and Therapeutic Molecules | November 2022 | October 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17982209 | METHODS AND COMPOSITIONS FOR TREATMENT OF A GENETIC CONDITION | November 2022 | February 2025 | Abandon | 28 | 0 | 1 | No | No |
| 18047014 | HUMANIZED IL-15 ANIMALS | October 2022 | March 2025 | Allow | 29 | 1 | 1 | Yes | No |
| 17934611 | NEW IMMUNOREGULATORY CELLS AND METHODS FOR THEIR PRODUCTION | September 2022 | August 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17934981 | IMPORTATION OF MITOCHONDRIAL PROTEIN BY AN ENHANCED ALLOTOPIC APPROACH | September 2022 | May 2024 | Abandon | 19 | 2 | 0 | No | No |
| 17932961 | NON-NATURALLY OCCURRING POLYADENYLATION ELEMENTS AND METHODS OF USE THEREOF | September 2022 | February 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17943533 | Animal Models and Therapeutic Molecules | September 2022 | November 2025 | Abandon | 39 | 2 | 0 | Yes | No |
| 17929495 | METHOD FOR PRODUCING PANCREATIC ENDOCRINE CELLS, AND TRANSDIFFERENTIATION AGENT | September 2022 | December 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17810029 | MOUSE COMPRISING A HUMANIZED TRKB LOCUS | June 2022 | April 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17855379 | Lineage Reprogramming to Induced Cardiac Progenitor Cells (iCPC) By Defined Factors | June 2022 | June 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 17837821 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY | June 2022 | January 2025 | Abandon | 31 | 0 | 1 | No | No |
| 17830011 | METHODS FOR TARGETED INSERTION OF DNA IN GENES | June 2022 | June 2024 | Allow | 24 | 1 | 0 | Yes | No |
| 17746181 | IMPORTATION OF MITOCHONDRIAL PROTEIN BY AN ENHANCED ALLOTOPIC APPROACH | May 2022 | June 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17740026 | PARTHENOGENIC ACTIVATION OF HUMAN OOCYTES FOR THE PRODUCTION OF HUMAN EMBRYONIC STEM CELLS | May 2022 | June 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17770728 | GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMAN OR CHIMERIC THPO | April 2022 | June 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17770406 | Methods For Treating And/Or Preventing Hypersomnias | April 2022 | March 2026 | Abandon | 47 | 1 | 1 | No | No |
| 17712003 | METHODS FOR MODIFYING A GENOME | April 2022 | July 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17762629 | METHOD FOR ESTABLISHING DIABETES DISEASE MODEL DOG | March 2022 | September 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17697099 | AAV-MEDIATED DELIVERY OF ANTIBODIES TO THE INNER EAR | March 2022 | March 2024 | Allow | 24 | 4 | 1 | Yes | No |
| 17642768 | METHOD OF MAKING HUMAN MOUSE XENOGRAFTS | March 2022 | November 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17572978 | METHODS OF CULTURING A MAMMALIAN CELL | January 2022 | August 2025 | Allow | 44 | 4 | 0 | Yes | No |
| 17564729 | METHODS FOR SCREENING HOST CELLS EXPRESSING TARGET PROTEINS | December 2021 | January 2025 | Allow | 36 | 2 | 1 | Yes | No |
| 17618779 | MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS AND USES THEREOF | December 2021 | July 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17615041 | VECTOR-BASED THERAPY FOR THYROID DISEASE | November 2021 | March 2026 | Abandon | 52 | 2 | 1 | No | No |
| 17613368 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEMOCHROMATOSIS | November 2021 | June 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17532853 | METHODS OF TREATING LYSOSOMAL STORAGE DISEASES | November 2021 | June 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17611882 | Targeting Vector, Nucleic Acid Composition, and Method for Constructing Liver-injured Mouse Model | November 2021 | April 2023 | Abandon | 17 | 2 | 1 | No | No |
| 17519823 | DEFINITIVE ENDODERM | November 2021 | February 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17605932 | ENGINEERED CAS9 WITH BROADENED DNA TARGETING RANGE | October 2021 | August 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17502944 | REGENERATING FUNCTIONAL NEURONS FOR TREATMENT OF DISEASE AND INJURY IN THE NERVOUS SYSTEM | October 2021 | May 2025 | Abandon | 43 | 2 | 0 | No | Yes |
| 17464774 | MODULATING CELL PROLIFERATION AND PLURIPOTENCY | September 2021 | November 2024 | Abandon | 38 | 2 | 0 | Yes | No |
| 17463007 | MAKING AND USING IN VITRO-SYNTHESIZED ssRNA FOR INTRODUCING INTO MAMMALIAN CELLS TO INDUCE A BIOLOGICAL OR BIOCHEMICAL EFFECT | August 2021 | March 2024 | Allow | 31 | 1 | 0 | Yes | No |
| 17412947 | ORGAN REGENERATION METHOD UTILIZING iPS CELL AND BLASTOCYST COMPLEMENTATION | August 2021 | December 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17392910 | AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR | August 2021 | April 2023 | Allow | 21 | 2 | 1 | Yes | No |
| 17371306 | ATOPIC DERMATITIS MODEL NON-HUMAN ANIMAL AND USE THEREOF | July 2021 | April 2025 | Abandon | 45 | 2 | 1 | No | No |
| 17371924 | GENE MODIFIED IMMUNE EFFECTOR CELLS AND ENGINEERED CELLS FOR EXPANSION OF IMMUNE EFFECTOR CELLS | July 2021 | June 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17341120 | TARGETED ELIMINATION OF BACTERIAL GENES | June 2021 | May 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17340752 | COMPOSITIONS FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION | June 2021 | November 2024 | Abandon | 42 | 2 | 1 | No | Yes |
| 17335727 | NON-HUMAN ANIMALS HAVING AN ENGINEERED IMMUNOGLOBULIN LAMBDA LIGHT CHAIN AND USES THEREOF | June 2021 | March 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17331097 | IMPORTATION OF MITOCHONDRIAL PROTEIN BY AN ENHANCED ALLOTOPIC APPROACH | May 2021 | March 2023 | Allow | 21 | 4 | 1 | Yes | No |
| 17244302 | HUMANIZED TRANSGENIC MOUSE MODEL | April 2021 | February 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17289188 | ANIMAL MODEL FOR AMPLIFYING HUMAN OR ANIMAL CIRCULATING TUMOR CELLS | April 2021 | December 2025 | Allow | 56 | 2 | 1 | Yes | No |
| 17236083 | HUMANIZED DIPEPTIDYL-PEPTIDASE IV (DPP4) ANIMALS | April 2021 | November 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 17235817 | METHOD FOR PRODUCING PANCREATIC ENDOCRINE CELLS | April 2021 | July 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17226125 | MOUSE HAVING A HUMANIZED B-CELL ACTIVATING FACTOR GENE | April 2021 | March 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17226611 | DIFFERENTIATION OF PLURIPOTENT STEM CELLS USING LAMININS LN-511, LN-521 AND LN-221 | April 2021 | March 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17217961 | CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS | March 2021 | August 2024 | Allow | 40 | 3 | 0 | Yes | No |
| 17275803 | METHODS FOR TREATMENT OF METHYLMALONIC ACIDEMIA | March 2021 | October 2025 | Allow | 55 | 2 | 1 | Yes | Yes |
| 17161801 | MOUSE HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GENE | January 2021 | October 2023 | Allow | 33 | 1 | 0 | Yes | No |
| 17264691 | Compositions for Identification of Membrane Targets for Enhancement of T cell Activity Against Cancer | January 2021 | February 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17163038 | ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOF | January 2021 | November 2022 | Abandon | 22 | 3 | 1 | Yes | No |
| 17163093 | ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOF | January 2021 | April 2022 | Allow | 14 | 2 | 1 | Yes | No |
| 17153636 | GROWTH FACTOR ANTAGONISTS FOR ORGAN TRANSPLANT ALLOIMMUNITY AND ARTERIOSCLEROSIS | January 2021 | August 2024 | Abandon | 43 | 2 | 0 | No | No |
| 17258516 | AAV COMPOSITIONS | January 2021 | October 2025 | Allow | 57 | 4 | 1 | Yes | No |
| 17134209 | METHOD FOR ACTIVATING IMMUNOCYTES IN VITRO | December 2020 | November 2024 | Abandon | 47 | 3 | 1 | No | No |
| 17119076 | PRODUCTION OF FERTILE XY FEMALE ANIMALS BY SILENCING OF GENES ON THE Y CHROMOSOME | December 2020 | March 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17117157 | ISOLATED NAIVE PLURIPOTENT STEM CELLS AND METHODS OF GENERATING SAME | December 2020 | March 2025 | Allow | 51 | 3 | 1 | Yes | No |
| 15734955 | TRANSGENIC CHICKEN THAT MAKES ANTIBODIES WITH LONG CDR-H3S STABILIZED BY MULTIPLE DISULFIDE BRIDGES AND DIVERSIFIED BY GENE CONVERSION | December 2020 | August 2025 | Allow | 56 | 3 | 1 | Yes | No |
| 16952002 | METHOD OF USING ADENO-ASSOCIATED VIRUS WITH VARIANT CAPSID | November 2020 | September 2021 | Allow | 10 | 2 | 0 | Yes | No |
| 16951984 | ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOF | November 2020 | September 2021 | Allow | 9 | 2 | 0 | Yes | No |
| 17048492 | ANTICANCER T CELL THERAPY PRODUCT-ASSISTING COMPOSITION COMPRISING DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY AND USE THEREOF | October 2020 | April 2024 | Abandon | 42 | 0 | 1 | No | No |
| 16981164 | MOUSE ARTIFICIAL CHROMOSOME VECTOR AND USE THEREOF | September 2020 | June 2025 | Allow | 57 | 3 | 1 | Yes | No |
| 16977951 | CELL PREPARATION FOR TREATMENT AND/OR PREVENTION OF ISCHEMIC DISEASE, AND METHOD FOR SCREENING CELL PREPARATION | September 2020 | November 2024 | Abandon | 51 | 2 | 1 | Yes | No |
| 16940277 | GENE THERAPY FOR DIABETIC NEUROPATHY USING AN HGF ISOFORM | July 2020 | April 2023 | Abandon | 32 | 1 | 0 | No | No |
| 16929042 | Osteogenic Differentiation of Bone Marrow Stem Cells and Mesenchymal Stem Cells Using a Combination of Growth Factors | July 2020 | February 2024 | Abandon | 43 | 1 | 0 | No | No |
| 16905557 | Animal Models and Therapeutic Molecules | June 2020 | January 2024 | Abandon | 43 | 5 | 1 | No | No |
| 16870413 | Animal Models and Therapeutic Molecules | May 2020 | December 2023 | Abandon | 44 | 5 | 1 | No | No |
| 16870365 | Animal Models and Therapeutic Molecules | May 2020 | June 2025 | Abandon | 60 | 7 | 1 | No | No |
| 16761911 | NON-HUMAN ANIMAL AND METHOD FOR PRODUCING SAME | May 2020 | April 2024 | Abandon | 47 | 2 | 1 | No | No |
| 16846321 | METHOD FOR PREPARING A LARGE ANIMAL MODEL WITH PERITONEAL CARCINOMATOSIS | April 2020 | August 2023 | Allow | 40 | 3 | 0 | Yes | No |
| 16650814 | CHIMERIC MOUSE COMPRISING STABLY TRANSPLANTED BAT CELLS | March 2020 | April 2024 | Allow | 49 | 2 | 1 | Yes | Yes |
| 16644267 | Customized Growth Factor Screening System for Cell Culture | March 2020 | October 2023 | Abandon | 44 | 2 | 1 | No | No |
| 16778524 | DNA-RESPONSIVE HYDROGELS | January 2020 | December 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 16775747 | P21-Activated Kinase Inhibitor Domain Targeted Transgenic Mouse | January 2020 | June 2023 | Abandon | 40 | 2 | 0 | No | No |
| 16744810 | HYDROGEL-BASED IMPLANTABLE DEVICE AND RELATED METHODS | January 2020 | January 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 16741513 | ADAM6 KNOCKIN MICE | January 2020 | December 2024 | Abandon | 59 | 4 | 1 | Yes | No |
| 16630589 | GENE THERAPY FOR TREATMENT OF INFERTILITY | January 2020 | November 2023 | Abandon | 46 | 2 | 1 | Yes | No |
| 16630420 | METHODS FOR GENERATING PLURIPOTENT STEM CELLS | January 2020 | March 2026 | Abandon | 60 | 6 | 1 | Yes | No |
| 16629396 | FISH EGG PROCESSING APPARATUS | January 2020 | January 2023 | Abandon | 36 | 1 | 0 | No | No |
| 16732400 | HUMANIZED IL-15 ANIMALS | January 2020 | July 2022 | Allow | 30 | 1 | 0 | Yes | No |
| 16731585 | MODULATING PHOSPHATASE ACTIVITY IN CARDIAC CELLS | December 2019 | June 2023 | Abandon | 42 | 4 | 1 | Yes | Yes |
| 16626059 | SINGLE LUNG CELL-DERIVED ORGANOIDS | December 2019 | September 2023 | Abandon | 45 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SINGH, ANOOP KUMAR.
With a 36.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SINGH, ANOOP KUMAR works in Art Unit 1632 and has examined 826 patent applications in our dataset. With an allowance rate of 36.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner SINGH, ANOOP KUMAR's allowance rate of 36.1% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SINGH, ANOOP KUMAR receive 3.19 office actions before reaching final disposition. This places the examiner in the 90% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by SINGH, ANOOP KUMAR is 43 months. This places the examiner in the 15% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +65.7% benefit to allowance rate for applications examined by SINGH, ANOOP KUMAR. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 7.4% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 28.9% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 140.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 88% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 88.3% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 86.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 59.7% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 3.5% of allowed cases (in the 81% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.7% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.